Gysgaça beýany

Barlagyň maksady: metabolik sindromynyň (MS) bejerişinde ösümlik garyndylarynyň netijeliligini öwrenmek. Kardiologiýa ylmy-kliniki merkezli hassahananyň iç keseller bölümine düşen MS bilen 31 näsag barlanyldy. Näsaglar 2 topara bölündi. Birinji topara gipolipidemik (statinler), antigipertenziw serişdeler (angiotenzin öwürji fermentiň ingibitorlary, kalsiý antagonistler), insulinrezistentligini peseltmegi üçin serişdeler (metformin) berildi. Ikinji topara esasy bejerişe goşmaça fitogaryndy bellenildi. Esasy we fitobejerginiň bilelikde ulanmagy, bejerginiň irki döwrinde öz netijeliligini görkezýär, keseliň geçişini gowulandyrýar we ýürek-damar gaýraüzülmeleriň ösmeginiň howpuny peseldýär.

Esasy sözler

Metabolik sindrom, anyklaýyş, fitobejergi.

Awtor barada

Annamyrat Allaberdiýew

---

Tylla Taňryberdiýewa

---

Enejan Hudaýgulyýewa

---

Edebiýatlar

1. Калашникова М.Ф. Метаболический синдром: современный взгляд на концепцию, методы профилактики и лечения // Эффективная фармакотерапия. Эндокринология.-2013.-Том.6.-№55- С. 5.

2. Учамприна В.А., Романцова Т.И., Калашникова М.Ф. Комплексный подход в лечении метаболического синдрома // Ожирение и метаболизм.-2014.-№ 1.-С. 32-37.

3. Учамприна В.А., Романцова Т.И., Калашникова М.Ф. Метаболический синдром: аргументы «за» и «против» //Ожирение и метаболизм.-2014.-№ 2.-С. 17-27.

4. Beltrán-Sánchez H. et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010 // Journal of the American College of Cardiology.-2013.-Vol. 62.-№ 8.-P.697–703.

5. Coltuc R.V., Stoica V. Metabolic syndrome - cardiovascular and metabolic, complex, difficult to quantify risk factor // Modern Medicine.-2016.-Vol.23.-№ 1. P.54-59.

6. Falkner B., Cossrow N.D. Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States // Current Hypertension Reports.-2014.-Vol.16.-№ 7.-P. 449.

7. Goldberg R.B., Mather K. Targeting the consequences of the metabolic syndrome in the diabetes prevention program //Arteriosclerosis, Thrombosis, and Vascular Biology.-2012.-Vol.32.-№9.-P. 2077–2090.

8. Kaur J. A comprehensive review on metabolic syndrome // Cardiology Research and Practice Volume.- 2014.-№4.-P.1-21.

9. Kaur J. Assessment and screening of the risk factors in metabolic syndrome // Medical Sciences.- 2014.-Vol.2.-№3.-P.140-152.

10. O'Neill S., O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies // Obesity Reviews.-2015.-№16.-P.1–12.

11. Onesi S.O., Ignatius U.E. Metabolic syndrome: Performance of five different diagnostic criterias // Indian Journal of Endocrinology and Metabolism.-2014.-Vol.18.-№ 4.-P.496-501.

12. Rodríguez A. Risk factors associated with metabolic syndrome in type 2 diabetes mellitus patients according to World Health Organization, third report national cholesterol education program, and international diabetes federation definitions // Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.-2011.- №4.-P.1-4.

13. Vancampfort D. et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables // Psychol. Med. 2013.-Vol.44.- №3.-P.1–12.

14. Willers J., Hahn A. Risk assessment using two different diagnostic tools: metabolic syndrome and cardiovascular risk Score (SCORE)–Data from a weight reduction intervention study // Food and Nutrition Sciences.-2013.-Vol.4.-№10.-P. 1028-1036.